Mesenchymal Stem Cells as a Therapeutic Approach for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, gradually destroying memory, learning, and functional independence. Current FDA-approved drugs such as donepezil, rivastigmine, galantamine, and memantine provide limited symptomatic relief but do not slow the progression of neuronal loss. Antibody therapies that target amyloid plaques have shown inconsistent regenerative medicine for neurodegenerative conditions outcomes.…